The COVID-19 Pandemic has caused a great concern worldwide. Myasthenia Gravis is known to be a challenging disease on its own. Most of the time the management of MG would include immunosuppression which could lead us to think that these patients may be at higher risk of contracting an infection or experience severe manifestations of COVID-19 [3]. Current data might be biased toward poor outcome of patients with myasthenia gravis with COVID-19; more likely to be hospitalized, have disease exacerbations, and have a higher risk for mortality than the general population with COVID-19. This case series will present how a concurrent COVID 19 infection affected the outcomes of patients with Myasthenia gravis. In our observation, other factors that may contribute to a poorer outcome are pregnancy and presence of other co-morbidities. The first case was pregnant. The second patient was undergoing treatment for pulmonary tuberculosis. The third case had more than two chronic illnesses and risk factors. In our setting, additional factors like accessibility to a health facility, proper patient education and availability of medications and equipment need to be considered. Despite improvement of myasthenic symptoms, there was progression of respiratory infection leading to poor outcome of the patients. For third-world countries like the Philippines, patient education and monitoring is very important for the prevention of hospitalization due to myasthenic crisis or COVID-19 infection. Further studies are recommended to establish the effects of pregnancy and other co-morbidities in the poor outcome of MG in COVID-19.
Read full abstract